Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-08-02
DOI
10.3389/fonc.2021.673213
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
- (2021) Bianca J. Lee et al. Nature Chemical Biology
- Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia
- (2020) Alexander Gavralidis et al. Current Hematologic Malignancy Reports
- Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- (2019) Iman Abou Dalle et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL
- (2019) Toby A. Eyre et al. HEMATOLOGICAL ONCOLOGY
- mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
- (2018) Moran Gotesman et al. Oncotarget
- Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia
- (2018) Qi Zhang et al. Oncotarget
- 4EBP1/c-MYC/PUMA and NF- B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells
- (2016) S. Yun et al. BLOOD
- Targeting mTOR for the treatment of B cell malignancies
- (2016) Jong-Hoon Scott Lee et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
- (2016) Hélène Malka-Mahieu et al. CLINICAL CANCER RESEARCH
- Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma
- (2016) Z. X. Ying et al. CLINICAL CANCER RESEARCH
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
- (2015) J. Pelletier et al. CANCER RESEARCH
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
- (2015) N. Daver et al. CLINICAL CANCER RESEARCH
- Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia
- (2014) A Schwarzer et al. ONCOGENE
- Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
- (2014) Sharmila Mallya et al. PLoS One
- Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)
- (2013) Karolina Nemes et al. PLoS One
- Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
- (2012) Z. Zeng et al. BLOOD
- Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
- (2012) M R Janes et al. LEUKEMIA
- Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
- (2011) M. Gupta et al. BLOOD
- Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
- (2011) J. K. Altman et al. CLINICAL CANCER RESEARCH
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
- (2010) Nathalie Carayol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
- (2010) R. J. O. Dowling et al. SCIENCE
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now